Welcome to our dedicated page for OKYO PHARMA SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain, dry eye disease, and ocular inflammatory conditions. As a foreign private issuer, OKYO submits Form 6-K reports under the Securities Exchange Act of 1934, which furnish key company announcements to investors.
Recent 6-K filings referenced in public disclosures include exhibits covering share acquisitions by Panetta Partners Limited, an entity in which OKYO’s Executive Chairman has a beneficial interest, with details on the number of ordinary shares acquired on NASDAQ and updated total holdings. Other 6-Ks furnish announcements about clinical development milestones, such as the registration pathway and planned 100-patient multi-center trial of urcosimod in neuropathic corneal pain, as well as notices of management presentations at industry meetings like the Ophthalmology Innovation Summit and BIO-Europe.
Through Stock Titan, users can access these filings as they are made available from EDGAR and review the attached exhibits that describe OKYO’s clinical progress, regulatory plans, and significant ownership changes. AI-powered summaries help explain the contents of each filing in plain language, highlighting why a particular 6-K may matter for understanding OKYO’s development of urcosimod and its broader ophthalmology strategy.
For investors analyzing OKYO, this filings page offers a structured way to follow its ongoing disclosure record, from clinical trial updates and registration pathway discussions to insider-related share purchases reported via Form 6-K. The combination of real-time access and AI-generated insights can support more efficient review of OKYO’s regulatory communications.
OKYO Pharma Limited reports that the underwriter has partially exercised its option to buy extra shares from the company in a recent equity offering. Piper Sandler & Co. purchased an additional 1,109,060 ordinary shares on March 12, 2026, lifting total gross proceeds from the underwritten public offering to approximately $22 million before fees and expenses. This follows the initial sale of 10,815,000 ordinary shares at $1.85 per share, all issued by the company under an effective Form F-3 shelf registration.
OKYO Pharma Limited filed a Form 6-K highlighting that its abstract on urcosimod for neuropathic corneal pain (NCP) was accepted for presentation at the ARVO 2026 Annual Meeting in Denver. Chief Scientific Officer Raj Patil, Ph.D., will present first-in-human data showing clinically meaningful pain reduction on the Visual Analogue Scale and improved quality-of-life metrics in NCP patients.
The Phase 2a proof-of-concept trial of urcosimod, a novel non-opioid, preservative-free eye drop with dual pain-relieving and anti-inflammatory activity, also suggested potential restoration of corneal nerve structure. Urcosimod holds FDA Fast Track designation and the first IND clearance specifically for NCP, and OKYO plans to initiate an approximately 150-patient multicenter Phase 2b/3 study in the first half of this year.
OKYO Pharma Ltd reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen jointly beneficially own 4,058,445 Ordinary Shares, representing
The shares are held by Point72 Associates, LLC and the filing states Point72 Asset Management has shared voting and shared dispositive power over these 4,058,445 shares. The statement is submitted under a Joint Filing Agreement and lists the reporting parties' principal business address in Stamford, Connecticut.
OKYO Pharma Limited is offering 10,815,000 ordinary shares at $1.85 per share, raising about $20.0 million before underwriting fees. An additional 1,622,250 shares may be sold if the underwriters exercise their 30‑day option in full.
OKYO expects net proceeds of approximately $18.5 million, which it plans to use for clinical development of its product candidates, general corporate purposes and working capital. Shares outstanding will rise to 51,370,197 (or 52,992,447 if the option is fully exercised), creating immediate dilution of $1.54 per share compared with an as adjusted net tangible book value of $0.31.
The company is an emerging growth, clinical‑stage ophthalmology biotech focused on urcosimod for neuropathic corneal pain and dry eye disease. Its ordinary shares trade on the Nasdaq Capital Market under the symbol “OKYO,” and the offering is underwritten on a firm commitment basis by Piper Sandler.
OKYO Pharma Ltd disclosed that investor Jorey Chernett has filed Amendment No. 2 to a Schedule 13G reporting a significant stake in the company’s common shares. Chernett beneficially owns 3,802,194 shares, representing 9.45% of the outstanding common stock as of the event date.
The filing states that Chernett has sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. It also certifies that the securities were not acquired to change or influence control of OKYO Pharma Ltd, but rather as a passive investment.
OKYO Pharma Limited entered an underwriting agreement with Piper Sandler for an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share. The underwriter has a 30-day option to buy up to 1,622,250 additional shares at the same public price, less fees. Gross proceeds are expected to be approximately $20 million before discounts, commissions and expenses, with all shares sold by the company. Closing is expected on February 17, 2026, subject to customary conditions. OKYO plans to use net proceeds for clinical development of its product candidates, general corporate purposes and working capital. The deal is made under an effective Form F-3 registration, and an updated investor presentation is furnished to investors.
OKYO Pharma Limited is raising capital through an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, for expected gross proceeds of about $20 million before expenses and discounts. The underwriter also has a 30-day option to buy up to 1,622,250 additional shares, which would lift gross proceeds to roughly $23 million if fully exercised.
The company plans to use the net proceeds mainly to fund clinical development of its product candidates, along with general corporate purposes and working capital. OKYO, a clinical-stage biopharma focused on neuropathic corneal pain and inflammatory eye diseases, recently completed a successful phase 2 trial of its lead drug urcosimod and is planning a ~150-patient Phase 2b/3 study.
Dauntless Investment Group, LLC filed Amendment No. 3 to a Schedule 13G reporting a passive ownership position in OKYO Pharma Ltd. The firm reports beneficial ownership of 471,523 common shares, representing 1.17% of the class as of
Dauntless, a Delaware single family office/passive investor, reports no sole or shared voting power over OKYO shares. It has sole dispositive power over 360,352 shares and shared dispositive power over 111,171 shares, and certifies the holdings are not for changing or influencing control of OKYO Pharma.
OKYO Pharma Limited intends to offer and sell its ordinary shares in an underwritten public offering, with all shares to be issued by the company. The company expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares sold.
The deal will be made under an effective Form F-3 shelf registration, with Piper Sandler & Co. as sole book-running manager, and is subject to market conditions. OKYO plans to use net proceeds mainly to fund clinical development of its product candidates, as well as for general corporate purposes and working capital.
OKYO Pharma Limited is conducting a primary offering of ordinary shares on The Nasdaq Capital Market under its F-3 shelf registration. The shares will be sold through an underwritten public offering led by Piper Sandler, with an additional 30-day option for underwriters to buy more shares.
OKYO expects to use the net proceeds for clinical development of its product candidates, general corporate purposes and working capital. As an emerging growth company, it follows reduced reporting requirements and warns investors about high investment risk, potential dilution from this and future equity issuances, and the possibility of Nasdaq delisting if listing standards are not maintained.